• Publications
  • Influence
Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
TLDR
In this large cohort of patients managed in the real-world setting in Spain, OMV/PTV/r+DSV and LDV/SOF achieved high rates of SVR12, comparable to those observed in randomized controlled trials, with similarly good safety profiles.
Prevalence and Severity of Hepatopulmonary Syndrome and Its Influence on Survival in Cirrhotic Patients Evaluated for Liver Transplantation
TLDR
One‐fourth of the patients with cirrhosis who were evaluated for LT had HPS (mostly mild to moderate); the presence of HPS did not affect LT waiting list survival and patient prognosis did not worsen.
Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation.
TLDR
A quarter of patients with decompensated cirrhosis can be delisted as a result of clinical improvement, which appears to be remain stable in most patients, and delisting is a safe strategy that could spare organs and benefit other patients with a more urgent need.
Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end‐stage liver disease: Analysis of data from the Hepa‐C registry
TLDR
Baseline Model for End‐Stage Liver Disease (MELD score alone (cut‐off 18) was the best predictor of survival and in this setting, a MELD score ≥18 may help clinicians to identify those patients with a higher risk of complications and to individualize treatment decisions.
Evaluation of clinical safety of conversion to Advagraf therapy in liver transplant recipients: observational study.
TLDR
Although tacrolimus levels decreased initially after conversion to Advagraf therapy, 1:1 conversion is safe for liver transplant recipients andRenal function and liver biochemistry values demonstrated no significant change during follow-up.
Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma
TLDR
Entecavir and tenofovir achieved high biochemical and virological response in chronic hepatitis B and Renal function remained stable with both drugs, highlighting the importance of regular HCC surveillance even in patients withVirological suppression.
Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C.
TLDR
Antiviral therapy with DAAs was highly efficacious and safe in KT recipients and a non-negligible number of patients, most of them cirrhotic, developed mild allograft dysfunction and a significant proportion of patients required immunosuppression dose adjustment, warranting a close follow-up during therapy.
[Treatment approach of hepatocellular carcinoma in Spain. Analysis of 705 patients from 62 centers].
TLDR
The majority of HCC patients are diagnosed in Spain out of early detection programs, and this limits the chance for early diagnosis and effective therapy.
Effectiveness and safety of sofosbuvir‐based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real‐life cohort
TLDR
In patients with GT3 infection and cirrhosis, SVR12 rates were high with both SOF+DCV and SOF/LDV, with few serious adverse events, and the single factor associated with failure to achieve SVR was platelet count.
Response to a vaccination schedule with 4 doses of 40 microg against hepatitis B virus in cirrhotic patients evaluated for liver transplantation.
TLDR
The response rate to hepatitis B vaccine reached a little more than 30% in cirrhotic patients who received 3 or 4 doses, and may be considered in nonresponders after the third dose.
...
1
2
3
4
5
...